On Friday, Shares of Pfizer Inc. (NYSE:PFE), lost -0.23% to $34.28. For the trailing twelve months, the Return on assets value is 6.80%, ROE is 15.70%, and ROI is 8.90%.
The company attained the volume of 12,956,300 on Friday, as compared to its average volume of 26.03M shares.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Shares of National Bank of Greece S.A. (NYSE:NBG), declined -3.55% to $1.36, during its last trading session.
On Friday, Financial stocks remained narrowly mixed in late trade with the NYSE Financial Sector Index dropping about 0.1% while the S&P Financial 100 Index was up by about 0.1%.
National Bank of Greece S.A., together with its auxiliaries, provides diversified financial services. The company is involved in retail and commercial banking, asset administration, investment banking, brokerage, and insurance activities.
At the end of Friday’s trade, Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), gained 1.32% to $9.23.
On May 19, Achillion Pharmaceuticals, declared that it has reached a worldwide license and partnership arrangement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize one or more of Achillion’s lead hepatitis C virus (HCV) assets which comprise ACH-3102, ACH-3422, and sovaprevir.
Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion’s HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the partnership and all subsequent costs related to commercialization of the HCV assets.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.
Finally, Whiting Petroleum Corp. (NYSE:WLL), ended its last trade with -0.41% loss, and closed at $33.74, as oil prices have fallen over supply concerns following escalating geopolitical disturbance in the Middle East.
July Brent crude fell 25 cents at $66.29 a barrel and the US crude for July dipped 27 cents at $60.45 a barrel, Reuters stated.
Whiting Petroleum Corporation, an independent oil and gas company, acquires, explores, develops, and produces crude oil, natural gas liquids, and natural gas in the Rocky Mountains and Permian Basin regions of the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur
